- $6.54m
- $2.45m
- $34.07m
- 41
- 75
- 33
- 48
Annual balance sheet for Biofrontera, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 7.3 | 8.2 | 24.7 | 27.8 | 1.42 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.79 | 3.29 | 12.4 | 7.41 | 5.16 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 23.5 | 19.6 | 46.4 | 43.1 | 23.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.503 | 0.37 | 0.267 | 1.58 | 1.75 |
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 28.8 | 24.1 | 53.2 | 50.9 | 27.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11.7 | 4.42 | 13.8 | 20.9 | 18.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 58.9 | 18.3 | 41.9 | 27 | 23.1 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -30.2 | 5.83 | 11.3 | 23.9 | 4.79 |
Total Liabilities & Shareholders' Equity | 28.8 | 24.1 | 53.2 | 50.9 | 27.9 |
Total Common Shares Outstanding |